Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
NCT01021852
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
326
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Insomnia
Interventions
DRUG:
MK-6096
DRUG:
Dose-matched Placebo to MK-6096
Sponsor
Merck Sharp & Dohme LLC